Skip to main content
TipRanks
Go Ultimate75% OFF

Vivesto AB (OMA) AI Stock Analysis

0 Followers
DE:OMA

Vivesto AB

(Frankfurt:OMA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverage and equity cushionA debt-free balance sheet and substantial equity cushion give Vivesto greater financial flexibility than a highly leveraged development-stage biotech. This can support continued research investment and help absorb operating losses, although preserving that cushion depends on improving operations or securing funding.
Negative Factors
Near-zero revenue baseNear-zero reported revenue shows that Vivesto has not yet established a recurring commercial business capable of funding operations. Until a candidate is approved, partnered on meaningful terms, or commercialized, financial performance remains heavily dependent on development progress and available capital.

Vivesto AB (OMA) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:OMA-57.84%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 7.13M
Dividend Yield
―
Average Volume (3M)
3
Price to Earnings (P/E)
-5.3
Beta (1Y)
3.04
Revenue Growth
―
EPS Growth
35.54%
Country
Germany
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Vivesto AB Business Overview & Revenue Model

Company Description

Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its...

Vivesto AB Risk Analysis

Vivesto AB disclosed 67 risk factors in its most recent earnings report. Vivesto AB reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Vivesto AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:OMA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:NANEXASE:NANEXA67NeutralSEK 1.93B13.1987.15%―2370.13%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:NICASE:NICA46NeutralSEK 56.22M0.4923.67%―163.58%―
SE:SPAGOSE:SPAGO42NeutralSEK 35.77M-1.12-87.37%―-97.52%31.31%
SE:CLS.BSE:CLS.B41NeutralSEK 79.86M-1.22-66.41%―-47.42%44.01%
SE:SPECSE:SPEC40UnderperformSEK 20.68M-0.12-57.15%――78.15%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%DE:OMASE:CLS.BSE:SPECSE:NICASE:SPAGOSE:NANEXADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:OMA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:OMAVivesto AB0.59-0.83-58.37%
SE:CLS.BClinical Laserthermia Systems AB Class B1.65-5.41-76.67%
SE:SPECSpectraCure AB0.01-0.12-89.55%
SE:NICANanologica AB0.17-0.89-83.94%
SE:SPAGOSpago Nanomedical AB0.04-0.07-60.00%
SE:NANEXANanexa AB10.088.42505.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.